Indications for liver transplantation for chronic viral hepatitis, and therapies for controlling hepatitis B virus infection before and after transplantation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  McCaughan, Geoffrey W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; DIURETIC AGENT; FAMCICLOVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; VIRUS DNA;

ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTERIAL PERITONITIS; BRAIN DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DRUG INDICATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; PORTAL HYPERTENSION; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT INDICATION;

EID: 0033947570     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02118.x     Document Type: Conference Paper

References (24)

1. Yoshida EM, Lake JR. Selection of patients for liver transplantation in 1997 and beyond. Clin. Liver Dis. 1997; 1: 247.
2. Realdi G, Fattovich G, Hadziyannis S et al. and The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J. Hepatol. 1994; 21: 656-66.
3. Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 4: 1311-16.
4. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
5. Propst A, Propst T, Zangeral G, Ofner D, Judmaier G, Vogel W. Dig. Dis. Sci. 1995; 8: 1805-15.
6. Fattovich G, Giustina G, Schalm SW et al. and the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 1: 77-82.
7. Lucey MR, Brown KA, Everson GT et al. Minimal criteria for placement of adults on the liver transplant waiting list. Transplantation 1998; 66: 956-62.
8. Hoofnagle JH, Di Bisceglie, Waggner JG et al. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104: 116.
9. Perrillo RP, Tamburro C, Regenstein F et al. Low-dose titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908.
10. Singh N, Gayowski T, Wannstedt C et al. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63: 1415.
11. Fontana RJ, Keeffe EB, Soldevila C et al. Is lamivudine beneficial in HBsAg+ patients awaiting liver transplantation? Experience in 182 North American patients. Transplantation 1999; (Suppl. 16): A40.
12. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
13. Terrault N, Holland CC, Ferrell L et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transplant. 1996; 2: 132.
14. Kruger M, Tillmann H, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant. Surg. 1996; 2: 253.
15. Perrillo R, Rakela J, Dienstag J et al. Multicentre study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581.
16. Tillmann HL, Trantwein C, Bock T Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIG after liver transplantation. Hepatology 1990; 30: 244.
17. McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant associated infection: high resistance rates in treatment for recurrence but universal prevention if used as prophylaxis with very low dose HBIG. Liver Transplant. Surg. 1999 (in press).
18. Muller R, Samuel D, Fassatix L et al. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. J. Hepatol. 1994; 21: 1140.
19. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842.
20. Terrault N, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327.
21. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
22. Perrillo R, Rakela J, Martin P et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post transplantation. Hepatology 1997; 26: 260A.
23. Markowitz J, Martin P, Conrad A et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585.
24. McCaughan GW, Koorey D, Spencer J. Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant. Hepatology 1998; 28: 263A.